Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Key Prognostic Factors in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Evidence Based Systematic Literature and Medical Review

Bastian von Tresckow, Pau Abrisqueta Costa, Shivani Aggarwal, Christian Hampp, Laura Walsh, Eileen Thorley, Mohsin Shah, Qiufei Ma, Ana Jimenez Ubieto

Blood (2023) 142 (Supplement 1): 7258.

https://doi.org/10.1182/blood-2023-179927

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Medicare-Insured Patients in the US with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Sikander Ailawadhi, Thomas Delea, Aaron Moynahan, Wenzhen Ge, Christian Hampp, Alexi Archambault, Ning Wu, Karen Rodriguez Lorenc, Irene Noguera-Troise, Glenn S. Kroog, Yariv Houvras, Qiufei Ma

Blood (2023) 142 (Supplement 1): 912.

https://doi.org/10.1182/blood-2023-188562

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Real-World Study of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Medicare Patients in the United States

Thomas Delea, Aaron Moynahan, Wenzhen Ge, Xue Song, Glenn S. Kroog, Irene Noguera-Troise, Karen Rodriguez Lorenc, Qiufei Ma

Blood (2023) 142 (Supplement 1): 3773.

https://doi.org/10.1182/blood-2023-188591

Published: 2023

Journal Articles

Key Prognostic Factors in Patients with Relapsed/Refractory Follicular Lymphoma: An Evidence Based Systematic Literature and Medical Review

Ana Jimenez Ubieto, Pau Abrisqueta Costa, Christian Hampp, Shivani Aggarwal, Mohsin Shah, Laura Walsh, Eileen Thorley, Qiufei Ma, Bastian von Tresckow

Blood (2023) 142 (Supplement 1): 7261.

https://doi.org/10.1182/blood-2023-186303

Published: 2023

Journal Articles

Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020

Sikander Ailawadhi, Qiufei Ma, Jessica J. Jalbert, Mo Zhou, Zheng-Yi Zhou, Nathaniel Downes, Adina Zhang, Lei Chi, Christian Hampp, Xue Song, Irene Noguera-Troise, Jonathan Weyne, Glenn S. Kroog, Karen Rodriguez Lorenc

Blood (2022) 140 (Supplement 1): 5272–5273.

https://doi.org/10.1182/blood-2022-158401

Published: 2022

Journal Articles

Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Blood (2022) 140 (Supplement 1): 8065–8067.

https://doi.org/10.1182/blood-2022-158418

Published: 2022

Journal Articles

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Qiufei Ma, Xue Song, Thomas E. Delea, Glenn S. Kroog, Wenzhen Ge, Lei Chi, Aaron Moynahan, Derek Weycker, Karen Rodriguez Lorenc

Blood (2022) 140 (Supplement 1): 5298–5300.

https://doi.org/10.1182/blood-2022-158142

Published: 2022

Journal Articles

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Wenzhen Ge, Alexi Archambault, Thomas E. Delea, Karen Rodriguez Lorenc, James Harnett, Aaron Moynahan, Derek Weycker, Yariv Houvras, Glenn S. Kroog, Ning Wu, Christian Hampp, Qiufei Ma

Blood (2022) 140 (Supplement 1): 10897–10899.

https://doi.org/10.1182/blood-2022-158013

Published: 2022

Journal Articles

Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)

Blood (2022) 140 (Supplement 1): 5198–5200.

https://doi.org/10.1182/blood-2022-158419

Published: 2022

Journal Articles

Treatment Preferences Among Patients with Diffuse Large B-Cell Lymphoma: A Survey across Western Europe and the United States of America

Patrick Connor Johnson, Ruben G.W Quek, Abigail Bailey, Neil Milloy, Isaac Sanderson, Qiufei Ma

Blood (2021) 138 (Supplement 1): 4565.

https://doi.org/10.1182/blood-2021-148459

Published: 2021

Journal Articles

Real-World Health-Related Quality of Life in Patients with Diffuse Large B-Cell Lymphoma: Comparisons with Reference Populations and By Line of Therapy

Qiufei Ma, Abigail Bailey, Neil Milloy, Jake Butcher, Ruben G.W Quek, Patrick Connor Johnson

Blood (2021) 138 (Supplement 1): 4111.

https://doi.org/10.1182/blood-2021-152798

Published: 2021

Journal Articles

Systematic Literature Review of the Clinical Efficacy, Safety, and Patient-Reported Outcomes of Treatments in Patients with Relapsed or Refractory Follicular Lymphoma after Two Prior Therapies

Qiufei Ma, PhD, Simarjeet Kaur, Angela Zhao, Jie Zhang, PhD, Roberto Javier Ramos, MD, Dinesh Kumar, Lokho John, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-137769

Published: 2020

Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD

Blood (2019) 134 (Supplement_1): 4719.

https://doi.org/10.1182/blood-2019-122587

Published: 2019

NARROW

Key Prognostic Factors in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Evidence Based Systematic Literature and Medical Review

Incidence of Second Primary Malignancies in Medicare-Insured Patients in the US with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Real-World Study of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Medicare Patients in the United States

Key Prognostic Factors in Patients with Relapsed/Refractory Follicular Lymphoma: An Evidence Based Systematic Literature and Medical Review

Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020

Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)

Treatment Preferences Among Patients with Diffuse Large B-Cell Lymphoma: A Survey across Western Europe and the United States of America

Real-World Health-Related Quality of Life in Patients with Diffuse Large B-Cell Lymphoma: Comparisons with Reference Populations and By Line of Therapy

Systematic Literature Review of the Clinical Efficacy, Safety, and Patient-Reported Outcomes of Treatments in Patients with Relapsed or Refractory Follicular Lymphoma after Two Prior Therapies

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only